 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||||||||
 |
 |
 |
|
|||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|||
 |
|
|||||||||||||||
 |
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
 |
|
||||||||
The 14th Annual BIO CEO & Investor ConferenceFebruary 13-14, 2012 - Waldorf Astoria, New York CityTitan Pharmaceuticals’ Presentation: Monday, February 13, 2012 at 9:00am ETWebcast URL: http://www.veracast.com/webcasts/bio/ceoinvestor2012/51103193.cfm |
|||||||||
 |
|
||||||||
 |
 |
 |
|
||||||
 |
 |
 |
Patients Report High Satisfaction, Decreased Opioid Dependence Problems and SOUTH SAN FRANCISCO, CA February 9, 2012 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced the results of an open-label, six-month safety re-treatment study (PRO-811) of patients with opioid dependence who previously completed a full six months of treatment in Titan’s confirmatory Phase 3 clinical trial of the investigational drug Probuphine™. SOUTH SAN FRANCISCO, CA February 6, 2012 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that company President Sunil Bhonsle will present during the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012 at 9 a.m. ET. The presentation will be webcast from the conference being held in New York City. To access the presentation online, please visit www.titanpharm.com or http://www.veracast.com/webcasts/bio/ceoinvestor2012/51103193.cfm. A replay of the webcast will be made available through the link on the Titan website approximately 24 hours after the live presentation and the replay will be archived for 90 days. SOUTH SAN FRANCISCO, CA December 21, 2011 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that its board of directors has approved the adoption of a Stockholder Rights Plan and the filing of a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC) for the possible future sale of Titan securities.
Company Receives Final Meeting Minutes from the U.S. Food & Drug Administration SOUTH SAN FRANCISCO, CA December 1, 2011 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that final minutes of its Pre-New Drug Application meeting regarding Probuphine™, an innovative subcutaneous implant formulation of the marketed drug buprenorphine, have been received from the U.S. Food and Drug Administration (FDA) and confirm the previously announced regulatory path for the program. 
|
 |
 |
 |
|
||
 |
 |
|
|||||||
Fanapt® (iloperidone)
On May 6, 2009 Fanapt, an atypical antipsychotic drug, was granted marketing approval by the US Food & Drug Administra-tion for the treatment of adult patients with schizophrenia. More... » »
Probuphine™
Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following a single treatment. This product is in Phase 3 development and has already demonstrated strong positive results... More... » » |
Titan Pharmaceuticals, Inc. is a biopharmaceutical company with valuable assets in the CNS (central nervous system) area. On May 6, 2009, US Food & Drug Administration granted marketing approval to Fanapt® (iloperi-done) for the treatment of adult patients with schizophrenia. This milestone represents the first marketing approval for a product out-licensed by Titan. The global sales from atypical antipsycho-tics, the same class of drugs like Fanapt®, exceeded $20 billion in 2007. Titan is entitled to receive 8-10% of global annual sales as royalty revenue, which may commence as early as the end of 2009. Read more... » » | |
|||||||